The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
 
Robert Lentz
Consulting or Advisory Role - Agenus (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Natera (Inst)
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); Guardant Health (Inst); Lilly (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - KAHR Medical
 
Matthew Ng
Stock and Other Ownership Interests - Amgen; AstraZeneca; GlaxoSmithKline
Honoraria - Amgen; Astellas Pharma; AstraZeneca/Daiichi Sankyo; MSD Oncology
Consulting or Advisory Role - Amgen; Astellas Pharma; BeiGene; MSD Oncology
Speakers' Bureau - MSD Oncology
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Astellas Pharma; AstraZeneca
Speakers' Bureau - AstraZeneca; BMS; DKSH; Eisai; Merck KGaA; MSD Oncology; Taiho Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); MSD (Inst); Novartis (Inst); SCG Cell Therapy (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; GT Aperion; Guardant Health; Harbinger Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Inderjeet Singh
No Relationships to Disclose
 
Venkateshan Srirangam
No Relationships to Disclose
 
Julienne Cometa
No Relationships to Disclose
 
Stephanie Blanchard
No Relationships to Disclose
 
Ranjani Nellore
No Relationships to Disclose
 
Kunal Shah
Employment - HOYA Techonosurgical (I)
Stock and Other Ownership Interests - Multiple public listed companies
 
Yock-Ann Lee
No Relationships to Disclose
 
Chek Shik Lim
No Relationships to Disclose
 
Bong Hwa Gan
No Relationships to Disclose
 
Alison Tan
No Relationships to Disclose
 
Nurul Rozaini
No Relationships to Disclose
 
Claudia Koh
No Relationships to Disclose
 
Nur Adanani
No Relationships to Disclose
 
Joe Yeong
Travel, Accommodations, Expenses - Roche
 
Veronica Diermayr
Employment - A*STAR; Experimental Drug Development Centre (EDDC)/A*STAR
Patents, Royalties, Other Intellectual Property - Patent: diagnostic test for ETC-159; Patent: ETC-159 combination therapy with pembrolizumab